TWST
Twist Bioscience Corporation
Price as of Jul 20, 2026
TWST earnings
Twist Bioscience Corporation earnings
Reported EPS and revenue history, upcoming estimates and available earnings-call summaries.
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| May 4, 2026 | $-0.49 | $-0.62 | -26.5% | $111M | +2.9% |
| Feb 2, 2026 | $-0.48 | $-0.50 | -4.2% | $104M | -3.7% |
| Nov 14, 2025 | $-0.50 | $-0.45 | +10.0% | $99M | +1.7% |
| Feb 3, 2025 | $-0.62 | $-0.53 | +14.5% | $89M | +2.0% |
| Nov 18, 2024 | $-0.71 | $-0.59 | +17.4% | $85M | +2.4% |
| Aug 2, 2024 | $-0.79 | $-0.86 | -8.9% | $81M | -0.9% |
| May 2, 2024 | $-0.84 | $-0.79 | +6.0% | $75M | -2.7% |
| Feb 2, 2024 | $-0.80 | $-0.75 | +6.3% | $71M | +5.8% |
| Nov 17, 2023 | $-0.94 | $-0.81 | +13.8% | $67M | +5.7% |
| Aug 4, 2023 | $-1.14 | $-1.01 | +11.4% | $64M | +5.3% |
| May 5, 2023 | $-1.09 | $-1.06 | +2.8% | $60M | +6.2% |
| Feb 3, 2023 | $-1.09 | $-0.74 | +32.1% | $54M | -0.3% |
Earnings call summary
Q2 FY2026 · May 4, 2026
AI summary of management’s prepared remarks and analyst Q&A. For informational purposes only — not investment advice.
Management highlights
- Twist posted 13th quarter of sequential revenue growth and outperformed broader lifetime tools market. - Twist Core Technology Advantage is semiconductor-based DNA synthesis platform providing cost, scale, speed advantage. - DNA synthesis and protein solutions grew 28% powered by AI-enabled drug discovery, with work with AWS on Amazon BioDiscovery as validation. - NGS tools business is durable and growing, strong in oncology diagnostics, with target enrichment and lab prep solutions. - Plan to accept more sequences and improve acceptance rates, anchored strategy around end applications with depth and breadth across biological continuum. - Deliberate investment in commercial organization and digital infrastructure to support growth.
Guidance
For fiscal 2026, expect total revenue of $442 million to $447 million, growth of approximately 17% to 19%. For Q3 of fiscal 2026, expect total revenue of $114 million to $115 million, growth of approximately 19% year-over-year at midpoint. Expect NGS to be driver of sequential growth in H2 and return to 20% growth by Q4. Expect reaching adjusted EBITDA breakeven for fourth quarter of fiscal 2026.
Segment performance
Total revenue grew to $110.7 million, up more than 19% year-over-year. DNA synthesis and protein solutions grew 28%, with revenue increasing to $53.3 million. NGS applications grew 12% year-over-year and 9% sequentially, with revenue reaching approximately $57.4 million. America's revenue increased to approximately $64.3 million, EMEA revenue rose to $37.3 million, APAC revenue increased to $9.1 million. Therapeutics revenue rose to $40.8 million, diagnostics revenue was $40 million, industry and applied revenue was $5.8 million, academic research and government revenue was $12.8 million, global supply partner revenue was $11.4 million. Gross margin expanded to 51.6% versus the prior year.
Analyst Q&A
Q: Discuss how AI-driven workflows performed in the quarter relative to internal expectations and contribution to updated fiscal guidance.
A: SPS grew 28% year-over-year, AI-driven discovery increased number of sequences and overall value of deals.
Q: How much of therapeutics 55% growth in second quarter was driven by AI-related programs?
A: AI has been source of strength, with many accounts driving growth now, not just a few.
Q: On academic and government end market, are things stabilizing or improving?
A: Academic end market suffering from funding pressures but Twist taking market share with premium discount.
Q: On gross margin, was down nominally sequentially. Any callout?
A: Deliberate investment in IGG and characterization for AI discovery projects and digital capabilities, confident in 52% guide for year.
Q: Follow up on gross margin improvement and automated workflows.
A: Front end is silicon chip, backend varies by product, adding automation on needed branches, and automating automation.
Q: You increased full-year revenue guidance. Any specific area driving increase?
A: Back half improvements, continued increases in DSPS revenue, opportunity to get new customers into DSPS side.
Q: Timeline for complex DNA offering products and additional opportunity.
A: Focused on customer experience, goal is one-stop shop, broad sequence acceptance, looking forward to scaling in coming quarters.
Q: On margin side, how to think about leverage beyond adjusted EBITDA breakeven in fourth quarter?
A: Laser focused on crossing adjusted EBITDA positives in Q4 while maximizing revenue growth, stewards of market, will discuss more at investor day.
Q: Color on genes for characterization this quarter and AI demand.
A: Growth in genes used internally to generate data, AI demand with customers shifting from bidding model to turning the crank.
Q: Pin in AI orders questioning, run rate for FY26 and revenue breakdown.
A: Predominantly AI discovery work driving outsized growth in therapeutics, hard to know exact number of discovery vs classic work.
Q: On diagnostics growth, incremental sequential growth through rest of year?
A: Seeing growth, confident in NGS part of business, portfolio of panels enables great growth, looking forward to return to growth.
Earnings history is derived from company filings and calendar data. Call summaries are grouped by reporting period. Latest covered event: 2026-08-03.